Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 1
1989 2
1991 3
1992 2
1993 4
1994 5
1995 3
1996 3
1997 6
1998 8
1999 6
2000 9
2001 5
2002 9
2003 6
2004 8
2005 11
2006 18
2007 10
2008 9
2009 10
2010 9
2011 6
2012 10
2013 10
2014 12
2015 14
2016 7
2017 3
2018 8
2019 5
2020 5
2021 9
2022 6
2023 3
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. Manjunatha R, et al. Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825. Indian J Pharmacol. 2016. PMID: 27127315 Free PMC article. Clinical Trial.
Because of their greater uroselectivity and minimal hemodynamic effects, alfuzosin, tamsulosin, and silodosin are generally preferred. The aim of this study was to compare the efficacy and tolerability of alfuzosin, tamsulosin, and silodosin in patients with …
Because of their greater uroselectivity and minimal hemodynamic effects, alfuzosin, tamsulosin, and silodosin are generally pr …
Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.
Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Mari A, et al. Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. eCollection 2021 Jan-Dec. Ther Adv Urol. 2021. PMID: 33912246 Free PMC article. Review.
Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. ...Alfuzosin is
Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Lee M. Lee M. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39. doi: 10.1093/ajhp/60.14.1426. Am J Health Syst Pharm. 2003. PMID: 12892027 Review.
The chemistry, pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of alfuzosin hydrochloride in the treatment of benign prostatic hyperplasia (BPH) are discussed. ...The extended-release (ER) formulations of alfuzosin for once- or t …
The chemistry, pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of alfuzosin hydrochloride in the …
Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR. Guay DR. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23. doi: 10.1016/s1543-5946(04)90003-7. Am J Geriatr Pharmacother. 2004. PMID: 15555475 Review.
Hepatic impairment has been found to significantly delay the elimination of alfuzosin IF, which constitutes a contraindication to use of the ER formulation. Renal impairment does not appear to exert clinically important effects on the pharmacokinetics of alfuzosi
Hepatic impairment has been found to significantly delay the elimination of alfuzosin IF, which constitutes a contraindication to use …
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
McVary KT. McVary KT. J Urol. 2006 Jan;175(1):35-42. doi: 10.1016/S0022-5347(05)00032-7. J Urol. 2006. PMID: 16406865 Review.
Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular. ...Although all alpha-blocking c …
Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, …
Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K, Plosker GL. McKeage K, et al. Drugs. 2002;62(4):633-53. doi: 10.2165/00003495-200262040-00009. Drugs. 2002. PMID: 11893233 Review.
The once-daily formulation of alfuzosin 10mg caused fewer vasodilatory adverse events than immediate-release alfuzosin 2.5mg three times daily and caused only slight decreases in systolic and diastolic blood pressure which were not clinically significant and …
The once-daily formulation of alfuzosin 10mg caused fewer vasodilatory adverse events than immediate-release alfuzosin
Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.
Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP. Liu C, et al. PLoS One. 2015 Aug 5;10(8):e0134589. doi: 10.1371/journal.pone.0134589. eCollection 2015. PLoS One. 2015. PMID: 26244843 Free PMC article. Review.
The adverse effects of Alfuzosin were similar to those of Tamsulosin (RR: 0.88; 95% CI, 0.61-1.26; p = 0.47). ...It is equivalent to Tamsulosin in its effectiveness and safety profile. Adverse effects should always be kept in mind when use this …
The adverse effects of Alfuzosin were similar to those of Tamsulosin (RR: 0.88; 95% CI, 0.61-1.26; p = 0.47). ...It is …
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Roehrborn CG. Roehrborn CG. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. doi: 10.1016/s0090-4295(01)01322-x. Urology. 2001. PMID: 11750253 Review.
Efficacy and safety of alfuzosin administered as 3-times-daily and 2-times-daily formulations have been previously demonstrated in placebo-controlled studies, and these formulations have been commercially available in many countries. ...Ejaculatory disorders were very rare …
Efficacy and safety of alfuzosin administered as 3-times-daily and 2-times-daily formulations have been previously demonstrated in pl …
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R, Wilt TJ. MacDonald R, et al. Urology. 2005 Oct;66(4):780-8. doi: 10.1016/j.urology.2005.05.001. Urology. 2005. PMID: 16230138 Review.
OBJECTIVES: To evaluate the efficacy and adverse effects of alfuzosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). ...Eight trials were placebo-controlled studies, two were alfuzosin versus alter …
OBJECTIVES: To evaluate the efficacy and adverse effects of alfuzosin for the treatment of lower urinary tract symptoms …
Alfuzosin-induced hepatotoxicity.
Zabala S, Thomson C, Valdearcos S, Gascón A, Pina MA. Zabala S, et al. J Clin Pharm Ther. 2000 Feb;25(1):73-4. doi: 10.1046/j.1365-2710.2000.00259.x. J Clin Pharm Ther. 2000. PMID: 10771467
We report a case of severe acute mixed hepatitis (cholestatic and hepatocellular), probably induced by alfuzosin. This event has not been reported previously (MEDLINE 1990, March 1999). Viral causes, autoimmune hepatitis and biliary tree obstruction were excluded. ...
We report a case of severe acute mixed hepatitis (cholestatic and hepatocellular), probably induced by alfuzosin. This event has not …
232 results